StockData
CytomX Therapeutics, Inc. logo

CytomX Therapeutics, Inc. (CTMX) stock

CTMXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/30
$1.94−0.05 (-2.27%)

Close on Nov 17, 2026Market cap $422.73MP/E –Yield –

CytomX Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

CytomX Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$87.15M, down 302.1% year over year. For fiscal 2025 it was -$22.36M, down 189.5% from the year before. The highest annual figure on record is $25.00M in fiscal 2024.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$22.36M-189.5%
FY2024Dec 31, 2024$25.00M–
FY2023Dec 31, 2023-$6.48M–
FY2022Dec 31, 2022-$101.34M–
FY2021Dec 31, 2021-$116.04M–
FY2020Dec 31, 2020-$80.54M–
FY2019Dec 31, 2019-$141.48M–
FY2018Dec 31, 2018-$77.87M–
FY2017Dec 31, 2017-$46.26M–
FY2016Dec 31, 2016-$59.59M–
FY2015Dec 31, 2015-$33.20M–
FY2014Dec 31, 2014-$29.77M–
FY2013Dec 31, 2013-$14.96M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$23.78M–
Q1 FY2026Mar 31, 2026-$19.67M-187.0%
Q4 FY2025Dec 31, 2025-$27.93M-258.0%
Q3 FY2025Sep 30, 2025-$15.77M-483.6%
Q2 FY2025Jun 30, 2025-$1.29M–
Q1 FY2025Mar 31, 2025$22.62M+94.1%
Q4 FY2024Dec 31, 2024$17.68M–
Q3 FY2024Sep 30, 2024$4.11M+31.6%
Q2 FY2024Jun 30, 2024-$8.45M–
Q1 FY2024Mar 31, 2024$11.66M–
Q4 FY2023Dec 31, 2023-$606.00K–
Q3 FY2023Sep 30, 2023$3.12M–
Q2 FY2023Jun 30, 2023-$3.35M–
Q1 FY2023Mar 31, 2023-$5.65M–
Q4 FY2022Dec 31, 2022-$9.51M–
Q3 FY2022Sep 30, 2022-$29.71M–
Q2 FY2022Jun 30, 2022-$30.05M–
Q1 FY2022Mar 31, 2022-$32.06M–
Q4 FY2021Dec 31, 2021-$34.90M–
Q3 FY2021Sep 30, 2021-$31.04M–
Q2 FY2021Jun 30, 2021-$26.70M–
Q1 FY2021Mar 31, 2021-$23.40M–
Q4 FY2020Dec 31, 2020-$24.07M–
Q3 FY2020Sep 30, 2020-$25.22M–
Q2 FY2020Jun 30, 2020-$25.76M–
Q1 FY2020Mar 31, 2020-$5.49M–
Q4 FY2019Dec 31, 2019-$67.97M–
Q3 FY2019Sep 30, 2019-$25.72M–
Q2 FY2019Jun 30, 2019-$31.23M–
Q1 FY2019Mar 31, 2019-$16.57M–
Q4 FY2018Dec 31, 2018-$25.81M–
Q3 FY2018Sep 30, 2018-$23.18M–
Q2 FY2018Jun 30, 2018-$13.26M–
Q1 FY2018Mar 31, 2018-$15.63M–
Q4 FY2017Dec 31, 2017-$1.25M–
Q3 FY2017Sep 30, 2017-$11.03M–
Q2 FY2017Jun 30, 2017-$25.37M–
Q1 FY2017Mar 31, 2017-$8.61M–
Q4 FY2016Dec 31, 2016-$14.23M–
Q3 FY2016Sep 30, 2016-$14.92M–

More CytomX Therapeutics figures

See a number that looks wrong?